Japanese pharmaceutical company Shionogi & Co. is actively exploring options to increase its manufacturing presence in the United States, specifically for antibiotics. This strategic shift is largely influenced by the potential for high tariffs on pharmaceuticals from the incoming Trump administration, prompting Shionogi to consider switching from exports to local production. The company is weighing the production of its antibiotic Fetroja (cefiderocol) in the US, anticipating it will become a key product as cases of antimicrobial resistance (AMR) continue to rise.
Shionogi's plans include the potential construction of a plant to produce cefiderocol, with the goal of initiating supply during the Trump administration. While no final decision has been made regarding a specific site or investment, the company is "actively" considering this option. In April 2026, Shionogi received a $119 million award from BARDA (Biomedical Advanced Research and Development Authority) to establish a US antibiotic manufacturing plant, further solidifying its intent to localize production.
Beyond establishing new plants, Shionogi is also looking into potential mergers and acquisitions in the US. This broader strategy aims to mitigate the impact of tariffs and strengthen its position in the American market. The company expects Fetroja, used to treat multi-drug resistant bacterial infections, to be a critical medicine in the coming years, underscoring the importance of securing its supply chain within the US.
